Digene SurePath “Not-Approvable” Letter Expected After FDA Data Request
This article was originally published in The Gray Sheet
Executive Summary
Digene will be required to submit additional clinical data to FDA to support its application for use of TriPath's SurePath test pack as a specimen collection medium for the Hybrid Capture 2 (HC2) human papillomavirus (HPV) test